KDR and cancer: There is strong evidence that antiangiogenic therapy using VEGF/VEGFR inhibitors can result in a clinical benefit for cancer patients [28] and this may not only be due to inhibition of vessel formation but also to direct action on VEGFR-2-positive cancer cells.